Report contents
Industry landscape
Where the company competes: concentrated drug buying, crowded medical insurance
Market structure: four firms set the terms of drug buying; medical coverage stays crowded. UnitedHealth Group sits on both sides of the US health care dollar. UnitedHealthcare takes premium from employers, CMS and state Medicaid programs and pays medical claims. Optum sells pharmacy benefits, care delivery and data and analytics into that same premium pool, including to payers that compete with UnitedHealthcare. Those are two different competitive arenas with two different structures, and the company's prospects depend on both.
Follow the dollar to see where margin accumulates. A plan sponsor pays a fixed amount per member per month; the plan then pays hospitals, physicians and drug costs, and keeps what is left after administrative expense. Two parties hold pricing power against it. Consolidated hospital systems and physician groups negotiate from a position of local scarcity, and CMS and state Medicaid agencies set rates administratively. The insurance link is also capped from above: under the Affordable Care Act, large-group plans must spend at least 85% of premium on medical care and quality improvement (80% for small-group and individual business), which limits how much administrative margin the risk-bearing business can retain. That floor is one reason the services link, where the PBM negotiates rebates with manufacturers and keeps a share, has carried a richer margin than underwriting.
Geography splits the two arenas cleanly. Employer group coverage is priced account by account, and the provider network that supports it is local, so a plan with deep hospital contracts in one metro carries little advantage into another. Medicare Advantage is bid county by county against a CMS benchmark each year, which means share can move at the county level in a single selling season. No comparable national share exists for medical coverage because the product is bought and priced that way. The services layer is the opposite: a national market with national fixed costs.
The drug benefit is where concentration is unambiguous. The American Medical Association's September 2026 analysis of 2024 data puts Optum Rx at 23% of US PBM lives, level with Express Scripts and ahead of CVS/Caremark and Prime Therapeutics:
| PBM (2024) | US share |
|---|---|
| Optum Rx | 23% |
| Express Scripts | 23% |
| CVS/Caremark | 18% |
| Prime Therapeutics | 11% |
| Top four combined | 75% |
The same study shows the top four rising from 70% of the market in 2022 to 75% in 2024, a gain of 5 percentage points in two years. Concentration is even tighter locally: the average Herfindahl-Hirschman Index (a standard concentration measure, where readings above 1,800 are usually treated as highly concentrated) across prescription drug plan regions was 2,574, and 94% of those markets were highly concentrated, up from 82% in 2022. Vertical integration is now the norm rather than the exception: 69% of prescription drug plan lives sat with an insurer that owns a PBM. That matters for UnitedHealth because its PBM is the largest single piece of national share it holds in any market.
Medical coverage looks nothing like that. Applying the practical test, commercial group insurance has far more than five meaningful competitors, counting the national carriers, the Blue Cross and Blue Shield licensees and regional plans, so entry barriers at the account level are moderate at best. Medicare Advantage is tighter, with UnitedHealth, Humana, CVS/Aetna, Kaiser Permanente and Centene among the significant bidders. The AMA data show UnitedHealth as the largest prescription drug plan insurer nationally in the commercial and Medicare Advantage segments and third in stand-alone plans, with concentration in those markets above the 1,800 threshold.
Barriers differ by link. The PBM link requires claims-processing scale, formulary leverage over manufacturers and compliance infrastructure for Medicare Part D rules, which is why four firms hold three-quarters of the business and why a new entrant is hard to finance. The insurance link requires state licenses, risk-based capital and a provider network, all replicable by a rival of similar size. Care delivery, where Optum Health competes against thousands of independent physician groups and hospital systems, has the lowest barriers of the three and no meaningful concentration at all. Size travels furthest in the PBM and analytics businesses, where fixed costs are national, and least in the local network business.
One structural shift is unsettled. The AMA notes that the Consolidated Appropriations Act passed this year requires rebates obtained by PBMs in Medicare Part D to be passed fully through to plan sponsors. If rebate retention shrinks, the PBM's economics migrate toward a flat administrative fee, and the 23% share buys less pricing power than it does today. How much of the current margin survives that rule is the open question this section leaves for the moat assessment.
Competitive advantage
Does the company have a moat? Yes, mostly on the Optum side
Overall moat rating: Fairly Strong. The protection is unevenly distributed. Optum, the fee-based arm of pharmacy benefits, care delivery and health data, competes in markets where national scale is expensive to copy. UnitedHealthcare, which produced $344.9 billion of the group's $447.6 billion of 2025 revenue, sells a contract that is repriced every year against rivals bidding for the same employer or the same county. Optum supplied roughly half of 2025 operating earnings, so the more protected half of the company is also the half carrying the profit.
Concentration on the fee side is the first support. Four firms held about three-quarters of US pharmacy benefit lives in 2024, up from 70% in 2022, according to the American Medical Association's September 2026 analysis. Returns follow the structure. Estimated after-tax return on invested capital averaged about 17.5% across FY2021 to FY2025, dropped to 11.1% in FY2025, then recovered to roughly 17% annualized in the nine months to September 30, 2026. Four strong years out of five are not by themselves a barrier; the fifth year is the useful test, because it shows which parts of the company hold up when medical costs move against it.
Market position: first by revenue, with the premium book no longer gaining
UnitedHealth is the largest US health insurer by revenue. Optum and UnitedHealthcare together generated $447.6 billion in 2025, with $168.0 billion of intercompany revenue eliminated, the company reported. In pharmacy benefits it tied for first at 23% of US lives in 2024, per the AMA study. In Medicare Advantage it is one of five national bidders rather than a dominant one, alongside Humana, CVS/Aetna, Kaiser Permanente and Centene.
The documented direction is down. UnitedHealthcare served 49.8 million people at December 31, 2025 and 48.3 million at September 30, 2026, a loss of 1.5 million in nine months, while third-quarter revenue came in at $112.7 billion against $113.2 billion a year earlier. A published estimate puts its Medicare Advantage enrollment share at 26%, down from 29%, though the estimate carries no dates. Those points do not add up to a five-year series, so share stability is not confirmed, and a share that swings more than 5 percentage points across five years usually signals no barrier while a move under 2 points points to a strong one. Market position: Fairly Strong. Position stability: Moderate.
Profitability: returns clear the bar, margins barely do
| USD bn, fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating income | 24.0 | 28.4 | 32.4 | 32.3 | 19.0 |
| NOPAT, estimated | 19.0 | 22.2 | 25.5 | 24.2 | 16.4 |
| Invested capital, estimated | 96.4 | 112.0 | 126.9 | 144.3 | 148.1 |
| After-tax ROIC, estimated | 19.7% | 19.8% | 20.1% | 16.8% | 11.1% |
| Operating margin | 8.3% | 8.8% | 8.7% | 8.1% | 4.2% |
NOPAT is operating income taxed at each year's effective rate; invested capital is equity plus total debt less cash. Goodwill of $110.5 billion is about three-quarters of the 2025 capital base, so most of the return is earned on assets that acquisitions created. The 13.5% tax rate in 2025 flattered that year: at 20%, ROIC would have been about 10.3%.
An average near 17.5% sits inside the 15%-25% band that usually separates a protected business from a competitive one. The margin does not. UnitedHealth's 4.2% operating margin in 2025 was the best among the five largest US insurers, but the next best came in around 3.6%, an estimate computed from reported results. On $447.6 billion of revenue, that gap is about $2.7 billion of operating income: real, and thin enough that a single bad bid cycle can close it. The company's own history shows the swing, from 8.8% in 2022 to 4.2% in 2025 and back to 7.0% in the first nine months of 2026.
The 2025 compression was an industry cost event, not share loss: rivals absorbed the same medical trend, and UnitedHealth still led on margin. Cycles do not erode moats. What would erode this one is failing to recover the cost through the next round of bids. Returns: Fairly Strong. Margins and scale: Moderate.
The overall rating leans on returns and on the concentration of the pharmacy layer, which is why it sits above the margin sub-rating. Strip out Optum and the remaining insurance book would rate Moderate on its own: annual repricing, five national bidders in Medicare Advantage and a compliance-driven cost base.
Where the advantage comes from: scale protects the fees, not the premiums
The test that matters most is how much of Optum's business stands on its own. Optum reported $270.6 billion of 2025 revenue against $168.0 billion of intercompany elimination, which puts revenue from outside the group at about $102.6 billion, or 38% of Optum and 23% of the group (an estimate, since a small part of the elimination may sit outside Optum). Three-fifths of Optum's revenue still comes from UnitedHealthcare. That is not disqualifying, but it means Optum's scale is partly manufactured by the parent's membership, and only the 38% sold to other payers has to win on price and service alone.
Economies of scale: the drug benefit carries the clearest barrier — Fairly Strong
Optum Rx tied for the largest share of US pharmacy lives in 2024 at 23%, and the top four held 75%, up 5 percentage points since 2022, the AMA found. Local concentration is tighter still: the average Herfindahl-Hirschman Index (a standard measure of market concentration, where readings above 1,800 are usually treated as highly concentrated) across prescription drug plan regions was 2,574, and 94% of those regions were highly concentrated.
The mechanism is a fixed-cost network that only pays off at national volume. Claims adjudication, formulary design, rebate negotiation with manufacturers, Part D compliance and provider contracting are largely fixed, so cost per claim falls as lives grow. Manufacturers negotiate rebates by volume, which means the largest buyers get terms a small entrant cannot match at any reasonable cost. Plan sponsors also face real friction in switching: a new PBM means re-implementing claims feeds, rewriting formularies and moving member communications, a project sponsors rarely undertake to chase a small per-member saving. That is structural protection, not superior execution, and the rising four-firm share is the evidence it is holding.
The break point is the Part D rebate pass-through rule described earlier. If rebate retention gives way to a flat administrative fee, the PBM's economics converge on a service contract, and 23% of lives buys much less pricing power. Optum's revenue per script and its segment margin are the places to watch it.
Demand-side advantage: members renew, but the renewal sets the price — Moderate
Both big books of business reprice on a calendar. Medicare Advantage bids are filed county by county against a CMS benchmark each year, and employer groups renew annually through brokers. Members do stay: comparing plans is tedious, provider networks change, and the default is to do nothing. That is habit and search cost, not captivity in the enterprise-software sense, because switching costs the member almost nothing in money.
The 2025 experience is the clearest evidence of the limit. When medical costs ran ahead of the rates already set, UnitedHealth could not reprice mid-year, and operating income fell $13.3 billion, from $32.3 billion to $19.0 billion, while revenue rose 11.8%. At 2025 premium volume, each point on the medical care ratio is worth about $3.5 billion, so the shortfall was close to four points. That is a cost cycle rather than proof that rivals can buy share with discounts, but the contract structure is what caps the captivity.
The ratio has since improved: 88.4% in the third quarter of 2026 against 89.9% a year earlier, or 89.1% excluding a $610 million reserve release. A second consecutive year above 89% without a matching rate increase in the 2027 bids would show the annual reset lagging permanently, and that, not a single bad quarter, is what would mark real erosion.
Regulation: the government sets the price in the largest line — Moderate
Medicare supplied 44% of 2025 revenue, mostly through Medicare Advantage, and CMS sets those rates administratively once a year. The Affordable Care Act's medical loss ratio floor, which requires large-group plans to spend at least 85% of premium on care and quality improvement, caps how much administrative margin the risk business can keep. Licenses, risk-based capital and provider-network adequacy keep small entrants out, which supports the concentration, but the same regulator that limits entry also sets the return. The unresolved Justice Department matter over risk-adjustment billing sits on top of that: it could change how the company earns its payments, and the outcome is not yet established.
False moats: integration is now standard among large rivals
Owning the pharmacy, the clinics and the data alongside the insurer looked distinctive a decade ago. It no longer is: CVS owns Aetna and Caremark, Cigna owns Evernorth, and Humana owns CenterWell. Integration is table stakes, and analytics get copied. The durable asset is narrower, a top-two position in a fee pool shared by four firms plus a membership that renews by default.
Two questions decide how long that lasts: does Optum Rx keep its rebate-based economics once Part D pass-through takes effect, and can the 2027 Medicare Advantage bids recover the 2025 cost trend? Optum's revenue per script and the medical care ratio will answer both before the group operating margin does.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Comparison and summaryHow UnitedHealth Group Incorporated compares with its closest rivals, and our moat rating
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
Business, moat and key questions
Open company page